Business
Equillium Announces Two Abstracts Accepted for Presentation at the 63rd ASH Annual Meeting and Exposition
LA JOLLA, Calif.--(BUSINESS WIRE)-- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and
About this update from Equillium, Inc.
[{"type":"text","content":" LA JOLLA, Calif.--(BUSINESS WIRE)--\nEquillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that two abstracts were accepted for presentation at the 63rd annual meeting of the American Society of Hematology to be held both in person and virtually, December 11 - 14, 2021.\n\nTitle: Itolizumab, a Novel Targeted Anti-CD6 Therapy, in Combination with Corticosteroids, Is Well-Tolerated, with Rapid Pharmacodynamic and Clinical Response in Newly Diagnosed Acute Graft-Versus-Host Disease\nFirst Author: Dr. John Koreth, associate professor of medicine, Dana Farber Cancer Institute, Harvard Medical School\nSession Name: 722. Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution: Poster II\nPublication Number: 2891\nSubmission ID: 145721\nDate: Sunday, December 12, 2021\nPresentation Time: 6:00 PM - 8:00 PM\nLocation: Georgia World Congress Center, Hall B5\n\nTitle: Antigenic Modulation of CD6 By Itolizumab Is a New Mechanism for Effector T Cell Inhibition\nFirst Author: Dalena Chu, Senior Research Associate, Equillium, Inc.,\nSession Name: 203. Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster I\nPublication Number: 995\nSubmission ID: 148805\nDate: Saturday, December 11, 2021\nPresentation Time: 5:30 PM - 7:30 PM\nLocation: Georgia World Congress Center, Hall B5\n\nIn addition to these presentations, abstracts will also be published online in the November supplemental issue of Blood.\n\nAbout Graft-Versus-Host Disease (GVHD)\n\nGVHD is a multisystem disorder that is a common complication of allogeneic hematopoietic stem cell transplants (allo-HSCT) caused by the transplanted immune system recognizing and attacking the recipient’s body. Symptoms of GVHD include rash, itching, skin discoloration, nausea, vomiting, diarrhea, and jaundice, as well as eye dryness and irritation.\n\nGVHD is the leading cause of non-relapse mortality in cancer patients receiving allo-HSCT, and its risk limits the number and type of patients receiving HSCT. GVHD results in high morbidity and mortality, with five-year survival of approximately 53% in patients who respond to steroid treatment and mortality as high as 95% in patients who do not respond to steroids. There are no approved ...